|

Trabectedin Clinical Trials

8 actively recruiting trials across 2 locations

▲ +1 trial since July 2026

Also known as: Dacarbazine, Gemcitabine, Trabectedin arm, Yondelis

Pipeline

Phase 1: 1Phase 2: 4Phase 3: 1Phase 1/2: 2

Top Sponsors

  • Sarcoma Oncology Research Center, LLC2
  • Italian Sarcoma Group2
  • Universität Münster1
  • UNICANCER1
  • M.D. Anderson Cancer Center1

Indications

  • Cancer8
  • Leiomyosarcoma2
  • Soft Tissue Sarcoma2
  • Leiomyosarcoma of Ovary1
  • Liposarcoma, Myxoid1

Other5 trials

Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
Phase 2
Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
Phase 2
Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
Phase 1/2
Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
Phase 2
tTF-NGR Randomized Study - STS
Phase 3

Santa Monica, California2 trials

Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma

Sant P Chawla

Phase 2
SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

Sarcoma Oncology Research Center

Phase 1/2

Houston, Texas1 trial

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

The University of Texas M. D. Anderson Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.